Last updated on October 2018

Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia

Brief description of study

To evaluate the long-term safety and tolerability of pimavanserin after 52 weeks of adjunctive treatment in subjects with schizophrenia

Clinical Study Identifier: NCT03121586

Contact Investigators or Research Sites near you

Start Over

Dragana Bugarski-Kirola, MD

State Psychiatric Hospital - Pazardzhik AD
Pazardzhik, Bulgaria
  Connect »